Out with the old, in with the new. What worked for small molecules and MAbs is irrelevant. We co-hosted this webinar with Impatient to help the audience uncover strategic frameworks, tailored for ATMP access challenges.
Team Inbeeo is ready for ISPOR Europe 2022 in Vienna.
Simply making essential cancer medicines more affordable does not guarantee that patients will receive the right medicine at the right time. Whilst essential cancer medicines are almost universally available in developed markets, what is industry currently doing to facilitate access to these medicines in LLMICs, who perhaps need it most?
All eyes were on pharma biotech companies in 2020, as they raced against each other to find solutions to alleviate the Covid-19 pandemic through vaccines and treatments.
Many market access decisions were intended to provide rapid one-off answers to one of the most extraordinary situations healthcare systems have ever had to face, but some of them are telling us something about the more profound changes that are likely to affect pharmaceutical market access in the longer run.
The Health Foundation and ICHOM are among the many stakeholders calling for an evolution of how we look at value in healthcare. Here are four trends emerging from their pledge.
Five tips worth keeping mind when planning for market access. An infographic.
I have learned the hard way that defining the value of a pharmaceutical innovation is not as easy as “Bob’s your uncle”.
Whatever happens next in the US and elsewhere, life science companies must take charge and own the value story behind their innovative products. It starts by understanding and mastering value assessment frameworks. An Inbeeo thought experiment.
Making sure your new product brings no bad budgetary news, clearly telling its value story, and pricing it fairly will help you convince your payer audience to fund it.
